Sold as Blincyto. Every FDA application for this active ingredient.
As of Nov 14, 2026, FDA lists 1 application for Blinatumomab (sold as Blincyto), first approved Dec 3, 2014, with 8 new uses approved and 0 published complete response letters.
| Blincyto | Part B | $101M | +17% | 397 |
| Blincyto | Part D | $1.5M | -10% | 0 |
| Venetoclax Plus Inotuzumab Reduced-Intensity Induction Sequentially Followed by Blinatumomab in B-ALLALL · Institute of Hematology & Blood Diseases Hospital, China | Not applicable | Not yet recruiting | Nov 6, 2026 |
| Asciminib-Based Induction Therapy for the Treatment of Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaB Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 · City of Hope Medical Center | Phase 1 | Not yet recruiting | Nov 3, 2026 |
| BLinatumomab and iNKT in Relapsed B-Cell ALLB-Cell ALL, ALL (Acute B-Lymphoblastic Leukemia) · UNC Lineberger Comprehensive Cancer Center | Phase 1 | Not yet recruiting | Oct 9, 2026 |
| Exploratory Study on the Efficacy and Safety of Low-Dose Blinatumomab in the Treatment of Moderate to Severe Primary Sjögren's SyndromePrimary Sjögren's Syndrome (pSS) · Beijing Tongren Hospital | Phase 2 | Not yet recruiting | Oct 1, 2026 |
| Immunotargeted Therapy Plus Low-Dose Chemotherapy in Newly Diagnosed Adult Ph+ B-ALLPh+ Acute Lymphoblastic Leukemia (Ph+ALL) · Institute of Hematology & Blood Diseases Hospital, China | Phase 2 | Not yet recruiting | Sep 25, 2026 |
| A Study of Injectable BLB101 and Blincyto® in Adult Participants With R/R CD19+ B-ALLPrecursor B-cell Acute Lymphoblastic Leukemia · Institute of Hematology & Blood Diseases Hospital, China | Phase 3 | Not yet recruiting | Jul 23, 2026 |
| Safety and Efficacy of the Bispecific T-Cell Engager (BiTE) as Conditioning Regimen for ABO-incompatible Living Donor Kidney TransplantationABO Blood Type Incompatible Kidney Transplantation · West China Hospital | Early phase 1 | Not yet recruiting | Jul 15, 2026 |
| Safety and Efficacy of BiTE in Desensitization Therapy for Highly Sensitized Kidney Transplant Candidates With cPRA ≥ 90%Kidney Transplantation Recipients, HLA Sensitization · West China Hospital | Phase 4 | Not yet recruiting | Jul 8, 2026 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Amgen